Application of sequencing technology has advanced our understanding of the molecular landscape of myelodysplastic syndromes (MDS). Recurrent driver mutations in genes implicated in epigenetic regulation, and functional modelling of the disease has proven the importance of epigenetic dysregulation in MDS pathogenesis. Although available therapies such as azacitidine and decitabine are thought to exert their effect by epigenetic modulation, deep understanding of disease biology and development of specific epigenetically targeted therapies is still an area under active research. In this editorial we will focus on the molecular basis of MDS with particular focus on epigenetic dysregulation and new agents under development targeting this group of biological processes.
Our understanding of the biology and pathogenesis of myelodysplastic syndromes (MDS) has evolved dramatically in the last two decades.
Evidence of an epigenetic background of the disease identified by a hypermethylation of specific genes and promoter-associated CpG islands was reported in the late 1990s 1 and first decade of this century. 2 Multiple sequencing efforts have shed light in the molecular annotation of the disease [3] [4] [5] [6] and have allowed to better group and dissect the different entities within this heterogeneous group of diseases. 7, 8 Dysregulation of epigenetic processes such as DNA methylation, histone modifications, miRNA and splicing machinery are essential in MDS pathogenesis and, in fact, multiple mutations and epimutations in well characterised epigenetically related genes such as DNTM3A, TET2, ASXL1, EZH2, IDH1/2 and splicing factors such as U2AF1, SF3B1, ZRSR2 and SRSF2 have been consistently described. [9] [10] [11] [12] Functional assays in cellular and murine models exploring the leukemogenic potential of such mutations have also confirmed these findings [13] [14] [15] [16] [17] [18] As a result of this, despite the complexity and heterogeneity of MDS pathogenesis, MDS can be considered, at least partially, an epigenetic disease.
Interestingly, recent studies by several groups including Jaiwal et al., 19 Xie et al. 20 and Genovese et al. 21 have confirmed that many of such mutations, particularly DNTM3A, TET2 and ASXL1 mutations, can be identified with increased frequency in elderly individuals with no evidence of haematological malignancy as part of what has been named clonal haematopoiesis of indeterminate potential (CHIP). This is particularly relevant considering haematopoietic stem-cell aging is likely one of the mechanisms implicated in MDS clonal initiation and progression 19, [22] [23] [24] and that these same mutations are known to participate in this aging process. Although approval of these agents led to a revolution of the treatment of these patients, reducing and delaying the risk of transformation to acute leukaemia and prolonging survival, only 40% of patients achieve responses to therapy and, in a majority of them, responses tend to be short-lived with eventual loss of response resulting in poor outcomes. [27] [28] [29] To 
